No insider purchase over the last 90 days. The latest, by 차바이오텍, was filed 08 May 2026.
Who traded when
BuySaleSince the insiders bought
- -14.3%Entry ₩4,530 · Close 22 Oct 2026 ₩3,880
- -14.3%Entry ₩4,530 · Close 22 Oct 2026 ₩3,880
- -26.7%Entry ₩5,290 · Close 22 Oct 2026 ₩3,880
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,350,000 shares10.27% mcap33.8% of flowKRXDART:20260511000468
- 0KRXDART:20260511000472
- 9,035,829 shares43.17% mcap53.8% of flowKRXDART:20260508000461
- 8,948,813 shares@ ₩2,664.0037.14% mcap46.2% of flowShareKRXDART:20260508000473Canonical exit: 29 Jul 2026 (T+90)
- 1,650,000 shares7.88% mcap36.9% of flowKRXDART:20260508000990
- ●Executives0DART
- 14,316 shares@ ₩6,327.000.14% mcap100.0% of flowShareKRXDART:20260401002354
- 1,650,000 shares13.50% mcap63.1% of flowKRXDART:20260325001321Canonical exit: 16 Jun 2026 (T+90)
- 3,948,813 shares32.32% mcap100.0% of flowKRXDART:20260325000239Canonical exit: 16 Jun 2026 (T+90)
- 2,350,000 shares20.87% mcap66.2% of flowKRXDART:20260324000927Canonical exit: 16 Jun 2026 (T+90)
- ●Executives0DART
- 3,700 sharesKRXDART:20250930000704Canonical exit: 22 Dec 2025 (T+90)
- 3,700 sharesShareKRXDART:20250925000247Canonical exit: 24 Dec 2025 (T+90)
- 365,585 sharesKRXDART:20250901000517
- 26,666 sharesShareKRXDART:20250409001913Canonical exit: 8 Jul 2025 (T+90)
- 80,677 sharesKRXDART:20250307000878
- ShareKRXDART:20231109000126
- ShareKRXDART:20231005000066
- ShareKRXDART:20231005000050
- ShareKRXDART:20230809000235
- ShareKRXDART:20230404002353
- ShareKRXDART:20230404000865
- ShareKRXDART:20230330000429
- ShareKRXDART:20220428000023
- ShareKRXDART:20220318000591
25 of 30 declarations
About AriBioLab Co.,Ltd.
Amounts reach tens of millions of euros at AriBioLab Co.,Ltd. (차백신연구소), a Korean health care company on the Korea Exchange valued at KRW 101.1 billion. Four purchases with an amount total EUR 38,522,192 (median EUR 9,866,361) and four sales with an amount total EUR 22,945,615 (median EUR 3,438,492).
On April 30, 2026, 차바이오텍 filed both the largest purchase, EUR 13,779,310, and the largest sale, EUR 16,016,458; 테라배터리솔루션 sold EUR 3,952,277 and 아리바이오투자목적15호조합 EUR 2,924,707 the same day. On March 18, 2026, 3 filers bought for EUR 24,742,882, including 소룩스 for EUR 11,990,413 and 테라배터리솔루션 for EUR 7,742,310.
Read moreShow less
In all, 30 filings were published from October 28, 2021 to May 11, 2026: 7 purchases and 8 sales, so 47% purchases. 고정재 (사내이사, inside director) filed 14 and 차바이오텍 7. Insiders and declared holders own 18.4% of the capital. With 11 filings, 2026 is the busiest year; 2025 has 5. Over twelve months: 4 purchases and 4 sales. Taking the 15 filings with a known delay, publication follows the trade by a median of 7 days.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
